Cubist Pharmaceuticals could get up to $98.5 mil. from partners Bristol, Merck, Pfizer in best case -- IPO.
CUBIST PHARMS COULD RECEIVE UP TO $98.5 MIL. FROM PARTNERS Bristol-Myers Squibb, Merck and Pfizer in research support payments, licensing fees, milestones and other payments if a successful drug candidate is commercialized from each of the programs in the collaborations, Cubist states in its prospectus for an initial public offering. The anti-infectives R&D firm entered into collaborations with Bristol and Merck in June and with Pfizer in December. Bristol made a $4 mil. equity investment in Cubist.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth